

ABSTRACT OF THE DISCLOSURE

A protective immune response against Chlamydial infection is achieved by *in vivo* administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor.

- 5 One of the vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia*, preferably *C. pneumoniae*, and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The other of the vectors comprises a second nucleotide sequence
- 10 encoding a 76 kDa protein of a strain of *Chlamydia*, preferably *C. pneumoniae*, and a promoter sequence operatively coupled to the second nucleotide sequence for expression of the 76 kDa protein in the host. The protection efficiency which is achieved by the immunization procedure is enhanced over that attained with the individual vectors alone.

552060" 9091660